Novavax storms back with $1.2B Sanofi deal May 10, 2024 By Lee Landenberger A licensing deal worth potentially up to $1.2 billion with Sanofi SA has breathed new life into Novavax Inc., which has struggled to compete in the COVID-19 space with powerhouses Pfizer Inc. and Moderna Inc. Read More
